What Changed for Ophthalmology ASC Billing in 2026?
Two CMS changes hit ophthalmology ambulatory surgery centers in 2026. First, Medicare cut the surgeon payment for routine cataract surgery (CPT 66984) by 11%, dropping it from $521.75 to $462.94, the largest single reduction in cataract reimbursement in three decades. Second, CMS implemented prior authorization requirements for eyelid surgeries (blepharoplasty and ptosis repair) and Botox procedures performed in ASCs, initially in seven states: California, Florida, Georgia, Maryland, New York, Pennsylvania, and Tennessee.
Cataract revenue dropped overnight. The 11% cut to CPT 66984 hits every high-volume cataract ASC, driven by a 2.5% efficiency adjustment to work RVUs and a reduction in indirect practice expense RVUs for facility settings.
Eyelid surgery now requires PA in 7 states. Claims for blepharoplasty, ptosis repair, and Botox in ASCs submitted without an approved prior authorization are denied outright in CA, FL, GA, MD, NY, PA, and TN.
The 2027 PFS proposes further cuts. The proposed 2027 rule would add a 3% endoscopy/ASC payment decrease and a 50% same-day modifier 25 reduction on top of the existing cataract cut.
How Much Did Cataract Surgery Payment Drop?
Under the 2026 Medicare Physician Fee Schedule, CPT 66984 (phacoemulsification cataract surgery with IOL implantation) now pays $462.94 for the surgeon’s professional fee, down from $521.75 in 2025. That is an 11% reduction, the largest single-year cut to cataract surgery reimbursement since the code was established. The ASC facility fee was corrected to $1,256 for 2026, up 3% from 2025 after CMS fixed a calculation error in the preliminary rate.
The cut was driven by two converging forces. CMS applied a 2.5% efficiency adjustment to work RVUs on non-time-based surgical codes, which hit cataract surgery directly. Simultaneously, CMS reduced the indirect practice expense allocation for services performed in facility settings, further compressing the professional fee. For a practice performing 20 cataract cases per week, the 11% surgeon fee reduction translates to roughly $1,200 per week in lost revenue, or more than $60,000 annually, before accounting for any commercial payer contracts that benchmark off Medicare. The fundus photography billing rules and other diagnostic imaging codes face similar facility-setting pressure, compounding the revenue squeeze on ASC-based ophthalmology practices.
| Component | 2025 | 2026 | Change |
|---|---|---|---|
| Surgeon fee (66984) | $521.75 | $462.94 | Minus 11% |
| ASC facility fee | $1,220 | $1,256 | Plus 3% (corrected) |
| Total ASC case payment | ~$1,742 | ~$1,719 | Minus ~1.3% |
| Conversion factor (non-QP) | $32.35 | $33.40 | Plus 3.26% |
| Work RVU efficiency adjustment | N/A | Minus 2.5% | Applied to surgical codes |
Which Eyelid Procedures Now Require Prior Authorization?
Effective January 1, 2026, CMS implemented a prior authorization requirement for certain eyelid and facial procedures performed in ambulatory surgery centers. The requirement currently applies in seven states: California, Florida, Georgia, Maryland, New York, Pennsylvania, and Tennessee. Claims submitted without an approved authorization are denied.
The affected procedures include blepharoplasty (CPT 15820 through 15823), ptosis repair (CPT 67901 through 67908), brow lift procedures, and Botox injections (CPT 64612, 64615) when performed in an ASC setting. The PA requirement does not apply to the same procedures performed in a physician office or hospital outpatient department, which creates a setting-specific compliance burden that many practices are still catching up on.
One question we hear constantly from practice managers is whether they can start the PA process before the patient is scheduled at the ASC. The answer is yes, and practices that build PA into the scheduling workflow rather than treating it as a day-of requirement see far fewer cancellations and denials. For practices also managing retinal OCT imaging claims, the frequency-based coverage limits on diagnostic codes create a parallel documentation burden that benefits from the same proactive workflow approach.
The 2026 cataract cut and eyelid PA requirements are compressing ASC revenue from both sides. A billing partner that manages global period compliance, PA workflows, and payer-specific cataract coding can recover the revenue a general biller misses. Comparing quotes is free.
How to Protect ASC Revenue in 2026
The practices that absorb these changes without a revenue drop share a common set of operational adjustments:
1. Renegotiate commercial contracts using the Medicare cut as leverage. If your commercial rates are benchmarked to Medicare, a 11% cut to 66984 drags your commercial cataract payments down unless you renegotiate the specific code’s rate or switch to a flat-rate arrangement.
2. Optimize premium IOL and LRIA billing. Femtosecond laser-assisted cataract surgery and premium IOLs carry patient-pay components that offset the Medicare surgeon fee reduction. Ensure your billing team captures every eligible LRIA charge.
3. Build PA into the scheduling workflow for eyelid cases. In the seven PA states, obtain authorization at the time of surgical scheduling, not after. A denied authorization discovered on the day of surgery costs more in rescheduling and patient dissatisfaction than the PA process itself.
4. Track the 90-day global period on every cataract case. With lower per-case reimbursement, every post-operative visit and complication follow-up that gets absorbed into the global period instead of billed separately (with the correct modifier) represents revenue you cannot afford to lose.
5. Monitor the 2027 PFS proposed rule for additional cuts. CMS proposed a further 3% ASC endoscopy payment decrease and a 50% same-day modifier 25 reduction for 2027. Model those on top of the 2026 cataract cut to see your full two-year exposure.
6. Audit your modifier usage on post-operative complications. The OIG has recommended CMS recover up to $123.9 million from ophthalmology claims by December 2026, with global period modifier errors as a primary target. Confirm every modifier 24, 78, and 79 claim is supported by documentation.
The OIG $123.9 Million Recovery Recommendation
The Office of Inspector General has recommended that CMS recover up to $123.9 million from ophthalmology claims by December 2026, targeting global period billing errors, duplicate modifier usage, and unsupported post-operative claims. The OIG report identifies patterns where post-operative visits, complication follow-ups, and unrelated same-week claims were billed without the correct modifier, causing them to be absorbed into the original surgical payment or triggering denials on audit. Across the billing companies we vet for ophthalmology practices, the practices most exposed are those performing high-volume cataract surgery without a calendar-based global period tracker. The visual field billing guide covers a parallel compliance issue where frequency-based documentation requirements protect against the same type of post-hoc audit risk.
Frequently Asked Questions
The Medicare surgeon fee for CPT 66984 dropped from $521.75 to $462.94, an 11% reduction. The cut was driven by a 2.5% work RVU efficiency adjustment on non-time-based surgical codes and a reduction in indirect practice expense RVUs for facility settings. It is the largest single-year cataract reimbursement cut in three decades.
As of January 2026, CMS requires prior authorization for blepharoplasty, ptosis repair, and Botox procedures performed in ASCs in seven states: California, Florida, Georgia, Maryland, New York, Pennsylvania, and Tennessee. The requirement does not apply to the same procedures in physician office or hospital outpatient settings.
No. The CMS prior authorization requirement applies only to eyelid surgeries and Botox procedures performed in ambulatory surgery centers, not in physician offices or hospital outpatient departments. Practices that perform these procedures in the office setting are not subject to the requirement.
It depends on your contract. Many commercial payers benchmark their surgical rates to the Medicare PFS, so an 11% Medicare cut can drag commercial rates down at the next contract renewal. Practices should proactively renegotiate cataract-specific rates or move to flat-rate arrangements that are not tied to the Medicare fee schedule.
The OIG has recommended that CMS recover up to $123.9 million from ophthalmology claims by December 2026, primarily targeting global period billing errors where post-operative visits and complication follow-ups were billed without the correct modifier (24, 78, or 79). Practices performing high-volume cataract surgery are the primary targets.
The CMS CY 2027 PFS proposed rule includes a 3% ASC and HOPD endoscopy/surgical payment decrease, a 50% same-day modifier 25 E/M reduction, and a conversion factor drop of 1.68%. The combined effect layers on top of the 2026 cataract cut. The comment period closed September 14, 2026, and the final rule is expected this fall.
Between the 11% cataract cut, new eyelid PA requirements, and the OIG’s $123.9 million recovery target, ophthalmology ASCs face more billing pressure in 2026 than any year in recent memory. A billing partner that manages global period compliance, PA workflows, and cataract modifier accuracy can protect the revenue a generalist biller loses. Billing Service Quotes matches your practice with vetted ophthalmology billing companies across all 50 states, with rates starting at 2.95%. Getting matched is free.
